Impact of corticosteroid doses on prognosis of severe and critical COVID-19 patients with Omicron variant infection: a propensity score matching study
Inflammopharmacology · 2024
DOI: 10.1007/s10787-024-01520-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Inflammopharmacology, 2024. Verfasst von Shiyao Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respir…. Hauptthemen laut MEDLINE: Propensity Score, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Background
There is lack of research on corticosteroid use for severe and critical COVID-19 patients with Omicron variant infection.
Methods
This multi-center retrospective cohort study involved 1167 patients from 59 ICUs across the mainland of China diagnosed with severe or critical SARS-CoV-2 Omicron variant infection between November 1, 2022, and February 11, 2023. Patients were segregated into two groups based on their corticosteroid treatment—usual dose (equivalent prednisone dose 30–50 mg/day) and higher dose (equivalent prednisone dose > 50 mg/day). The primary outcome was 28-day ICU mortality. Propensity score matching was used to compare outcomes between cohorts.
Results
After propensity score matching, 520 patients in the usual dose corticosteroid group and 260 patients in the higher dose corticosteroid group were included in the analysis, respectively. The mortality was significantly higher in the higher dose corticosteroid group (67.3%, 175/260) compared to the usual dose group (56.0%, 291/520). Logistic regression showed that higher doses of corticosteroids were significantly associated with increased mortality at 28-day (OR = 1.62,95% CI 1.19–2.21, p = 0.002) and mortality in ICU stay (OR = 1.66,95% CI 1.21–2.28, p = 0.002). Different types of corticosteroids did not affect the effect.
Conclusions
The study suggests that higher-dose corticosteroids may lead to a poorer prognosis for severe and critical COVID-19 patients with Omicron variant infection in the ICU. Further research is needed to determine the appropriate corticosteroid dosage for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of…
Förderung
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Wang, S., Chen, Z., Zhang, X., Wu, X., Wang, Y., Zhang, Q., Huang, L., Cui, X., Cai, Y., Huang, X., Xia, J., Gu, S., Li, M., & Zhan, Q. (2024). Impact of corticosteroid doses on prognosis of severe and critical COVID-19 patients with Omicron variant infection: a propensity score matching study. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01520-0
Vancouver
Wang S, Chen Z, Zhang X, Wu X, Wang Y, Zhang Q, et al. Impact of corticosteroid doses on prognosis of severe and critical COVID-19 patients with Omicron variant infection: a propensity score matching study. Inflammopharmacology. 2024. doi:10.1007/s10787-024-01520-0
BibTeX
@article{Wang2024,
author = {Wang, Shiyao and Chen, Ziying and Zhang, Xinran and Wu, Xiaojing and Wang, Yuqiong and Zhang, Qi and Huang, Linna and Cui, Xiaoyang and Cai, Ying and Huang, Xu and Xia, Jingen and Gu, Sichao and Li, Min and Zhan, Qingyuan},
title = {Impact of corticosteroid doses on prognosis of severe and critical COVID-19 patients with Omicron variant infection: a propensity score matching study},
journal = {Inflammopharmacology},
year = {2024},
doi = {10.1007/s10787-024-01520-0}
}
EUVIMED